Para continuar lendo confirme que você é um profissional da saúde.
-
Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD.
Targeting key proximal drivers of type 2 inflammation in disease.
Nat Rev Drug Discov. 2016;15(1):35-50. -
Israel E, Reddel HK.
Severe and difficult-to-treat asthma in adults.
N Engl J Med 2017;377:965-76. -
Wechsler ME, Ford LB, Maspero JF, Pavord ID, Tohda Y, Langton D, et al.
Late Breaking Abstract—Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE.
Eur Respir J. 2020;56:4613. - Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, et al.
Liberty Asthma QUEST: Phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma.
Adv Ther. 2018;35(5):737-48.
Referências